On November 9, a TradingView chart showed Bitcoin dominance dropping below 25%, a sharp deviation from the usual 60%+ range. However, this figure is a ratio of Bitcoin's market cap to the combined value of the top 125 cryptocurrencies, and can be distorted if the total market value is overstated or if the list of tracked coins changes. Therefore, the sudden drop does not indicate a real shift to altcoins or a market rally. No clear cause for this anomaly has been identified yet, and such one-time readings should be interpreted cautiously.
Bitcoin dominance below 25% on November 9 provides context for cryptocurrency market activity. For readers following crypto assets, here is Pluang's market snapshot as of Nov 10, 2026 21:51 WIB: of 50 major cryptocurrencies priced on Pluang, 14 rose and 35 fell today. Notable movers include SOL at Rp1,516,494 with a 3.92% decline and 73% sell order activity, BCH at Rp4,214,691 with a 3.67% decline but 90% buy order activity, and LUNC at Rp0.702 with a 3.66% decline and 79% buy order activity.
project44 has partnered with Snowflake to enhance supply chain decision-making through Mo, an AI-powered supply chain analyst. Mo uses project44's extensive logistics data and Snowflake Cortex AI to provide accurate, consistent answers to complex sup...
H&R Block has launched the Emerald Advance Loan, a fixed-rate short-term loan up to $1,750 with a 35.90% APR, designed to help families cover year-end expenses without monthly payments. Borrowers repay the loan in full by March 31, 2027, with no impa...
Duke Robotics has entered a strategic collaboration with Greek security firm CRONOS to commercialize its Insulator Cleaning Drone (IC Drone) technology in Greece. This partnership leverages CRONOS's strong presence in Greece's critical infrastructure...
Alm. Brand A/S repurchased 1,369,397 shares between November 3 and 9, 2026, at an average price of DKK 17.46 per share. This is part of their announced buy-back program totaling up to DKK 593 million, aiming to reduce the number of outstanding shares...
Novartis has secured first place in the 2026 Access to Medicine Index, maintaining its lead since 2024 by excelling across all assessed technical areas, including governance, R&D, and product delivery. The company scored 3.86 out of 5 overall, with a...
